We are live on
!
Find out more
EI
EAM Investors Portfolio holdings
AUM
$866M
1-Year Est. Return
377.14%
This Fund
S&P 500
This Quarter
Est. Return
+113.09%
1 Year Est. Return
+377.14%
3 Year Est. Return
+5,228.32%
5 Year Est. Return
+49,813.07%
10 Year Est. Return
+19,957,621.5%
AUM
$452M
AUM Growth
+$130M
(+40%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-4.08%
Top 10 Holdings %
Top 10 Hldgs %
10.66%
Holding
352
New
147
Increased
15
Reduced
84
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AWH
Aspira Women's Health Inc. Common Stock
AWH
|
+$3.03M |
| 2 |
OneSpan
OSPN
|
+$2.96M |
| 3 |
Anterix
ATEX
|
+$2.79M |
| 4 |
Calix
CALX
|
+$2.73M |
| 5 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
+$2.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Axsome Therapeutics
AXSM
|
+$3.54M |
| 2 |
Karyopharm Therapeutics
KPTI
|
+$3.44M |
| 3 |
Teladoc Health
TDOC
|
+$3.2M |
| 4 |
Krystal Biotech
KRYS
|
+$3M |
| 5 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$2.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 30.95% |
| 2 | Technology | 21.89% |
| 3 | Consumer Discretionary | 16.2% |
| 4 | Industrials | 10.05% |
| 5 | Consumer Staples | 6.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
Protolabs
PRLB
$2.16B
| $1.7M | 0.38% |
+15,151
| New | +$1.56M |
|
|
EVBG
127
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $1.7M | 0.38% |
12,264
-10,968
| -47% | -$1.43M |
|
128
Antero Resources
AR
$10.6B
| $1.69M | 0.37% |
+664,622
| New | +$1.74M |
|
129
Boot Barn
BOOT
$4.88B
| $1.68M | 0.37% |
+77,921
| New | +$1.52M |
|
130
PennyMac Financial
PFSI
$3.94B
| $1.68M | 0.37% |
40,144
-20,547
| -34% | -$651K |
|
131
Hexcel
HXL
$7.89B
| $1.67M | 0.37% |
+36,939
| New | +$1.31M |
|
132
Saia
SAIA
$9.52B
| $1.66M | 0.37% |
+14,898
| New | +$1.43M |
|
133
ScottsMiracle-Gro
SMG
$3.85B
| $1.65M | 0.36% |
12,236
-2,915
| -19% | -$376K |
|
134
Cytosorbents Corp
CTSO
$23.7M
| $1.63M | 0.36% |
164,400
+28,302
| +21% | +$260K |
|
135
Arcus Biosciences
RCUS
$3.48B
| $1.62M | 0.36% |
+65,606
| New | +$1.77M |
|
136
Woodward
WWD
$22B
| $1.62M | 0.36% |
+20,863
| New | +$1.36M |
|
137
Werner Enterprises
WERN
$2.27B
| $1.61M | 0.36% |
36,884
-3,041
| -8% | -$125K |
|
|
BIG
138
DELISTED
Big Lots, Inc.
BIG
| $1.61M | 0.36% |
+38,243
| New | +$1.09M |
|
139
Tandem Diabetes Care
TNDM
$1.38B
| $1.6M | 0.35% |
16,216
-16,164
| -50% | -$1.29M |
|
140
Williams-Sonoma
WSM
$29.2B
| $1.59M | 0.35% |
+38,828
| New | +$1.32M |
|
141
Sprouts Farmers Market
SFM
$7.94B
| $1.58M | 0.35% |
+61,925
| New | +$1.42M |
|
142
PAR Technology
PAR
$719M
| $1.57M | 0.35% |
52,625
-31,086
| -37% | -$680K |
|
143
AXT Inc
AXTI
$4.49B
| $1.56M | 0.35% |
+328,562
| New | +$1.55M |
|
|
MYOK
144
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $1.56M | 0.35% |
16,158
-2,081
| -11% | -$174K |
|
145
BioXcel Therapeutics
BTAI
$26M
| $1.56M | 0.34% |
1,835
-1,651
| -47% | -$1.08M |
|
|
CLDR
146
DELISTED
Cloudera, Inc.
CLDR
| $1.54M | 0.34% |
+121,090
| New | +$1.16M |
|
147
Opko Health
OPK
$1.01B
| $1.52M | 0.34% |
+446,989
| New | +$1M |
|
148
CryoPort
CYRX
$767M
| $1.5M | 0.33% |
+49,670
| New | +$1.11M |
|
149
Hain Celestial
HAIN
$50.3M
| $1.5M | 0.33% |
+47,566
| New | +$1.38M |
|
150
Trupanion
TRUP
$1.06B
| $1.49M | 0.33% |
+34,954
| New | +$1.13M |
|
Similar funds
RWM
MCM
HP
OMG
ICCFIA
WFAL
WCM
TSS
EAM Investors's Q2 2020 Portfolio in Review
As of Q2 2020, EAM Investors held 352 positions worth $452M, up 40% from $322M the previous quarter. Its ten largest holdings account for 11% of the portfolio.
EAM Investors withdrew a net $18.5M in Q2 2020, closing 97 positions and reducing 84 holdings. Its most notable exit was Karyopharm Therapeutics, an estimated $3.44M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 40% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, EAM Investors opened a new position in Aspira Women's Health Inc. Common Stock worth $2.61M.
- EAM Investors's largest Q2 2020 buy was Aspira Women's Health Inc. Common Stock: 45,313 shares worth $2.61M.
- EAM Investors added most to Purple Innovation in Q2 2020, an estimated $2.04M increase.
- EAM Investors's biggest Q2 2020 reduction was Axsome Therapeutics, cutting an estimated $3.54M.
- EAM Investors fully exited Karyopharm Therapeutics in Q2 2020, selling an estimated $3.44M.
- EAM Investors's ten largest holdings make up 11% of its $452M portfolio in Q2 2020.
- EAM Investors opened 147 new positions and closed 97 in Q2 2020.
- EAM Investors's portfolio value rose 40% quarter-over-quarter to $452M.
Based on EAM Investors's 13F filing for Q2 2020, filed 13 Aug 2020.